Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 31537466 | HLA-DRB1*11 | hemophilia a | Iranian | NA | NA | unclassified | |
| hla-drb1*01:01, but not hla-drb1:1503 or hla-drb1*11, is associated with decreased inhibitor risk in iranian hemophilia a patients. | |||||||
| 31537466 | HLA-DRB1*01 | hemophilia a | Iranian | NA | NA | unclassified | |
| hla-drb1*01:01, but not hla-drb1:1503 or hla-drb1*11, is associated with decreased inhibitor risk in iranian hemophilia a patients. | |||||||
| 31537466 | HLA-DRB1*11 | hemophilia a | Iranian | NA | NA | unclassified | |
| the goal of this study is to determine the association between hla-drb1*15:03, hla-drb1*11 and hla-drb1*01:01 alleles and fviii inhibitors in severe hemophilia a patients in iran.materials/ hla-drb1 genotyping was performed using multiplex sequences specific primers (pcr-ssp) in two groups of severe hemophilia a patients comprising 51 and 50 individuals with and without fviii inhibitors respectively. | |||||||
| 31537466 | HLA-DRB1*15 | hemophilia a | Iranian | NA | NA | unclassified | |
| the goal of this study is to determine the association between hla-drb1*15:03, hla-drb1*11 and hla-drb1*01:01 alleles and fviii inhibitors in severe hemophilia a patients in iran.materials/ hla-drb1 genotyping was performed using multiplex sequences specific primers (pcr-ssp) in two groups of severe hemophilia a patients comprising 51 and 50 individuals with and without fviii inhibitors respectively. | |||||||
| 31537466 | HLA-DRB1*01 | hemophilia a | Iranian | NA | NA | unclassified | |
| the goal of this study is to determine the association between hla-drb1*15:03, hla-drb1*11 and hla-drb1*01:01 alleles and fviii inhibitors in severe hemophilia a patients in iran.materials/ hla-drb1 genotyping was performed using multiplex sequences specific primers (pcr-ssp) in two groups of severe hemophilia a patients comprising 51 and 50 individuals with and without fviii inhibitors respectively. | |||||||
| 31537466 | HLA-DRB1*01 | hemophilia a | Iranian | NA | NA | unclassified | |
| an association between hla-drb1*01:01 and paucity of fviii inhibitor showed that this allele has probably a protective effect in severe hemophilia a patients in iran. | |||||||
| 34026790 | HLA (HLA) | hemophilia a | North American | NA | NA | unclassified | |
| hla variants and inhibitor development in hemophilia a: a retrospective case-controlled study using the athndataset. | |||||||
| 34506591 | HLA-CLASS II (HLA CLASS II) | hemophilia a | NA | NA | NA | unclassified | |
| polymorphisms in the hla class ii molecules and the cytotoxic t lymphocyte antigen 4 have been reported to be associated with the development of autoantibodies in acquired hemophilia a. | |||||||
| 34506591 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | factor xiii deficiency | NA | NA | NA | unclassified | |
| important roles of the human leukocyte antigen class i and ii molecules and their associated genes in the autoimmune coagulation factor xiii deficiency via whole-exome sequencing analysis. | |||||||
| 3929463 | HLA-DR (HLA-DR) | osteosarcomas | NA | NA | NA | positive+negation | |
| osteosarcomas were positive for vimentin and, in part, for hla-dr. other types of intermediate-sized filaments were not detected in tumour cells. | |||||||
Copyright 2024